Specify a stock or a cryptocurrency in the search bar to get a summary
Iconovo
ICOIconovo AB (publ) develops and licenses inhalation medications in Sweden. The company offers ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone Nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has collaboration agreement with the French biotechnology company Affilogic, ENA Respiratory Pty Ltd, and Stevanato Group, as well as licensing agreements with Kiox Pharma and Monash University. Iconovo AB (publ) was founded in 2013 and is headquartered in Lund, Sweden. Address: Ideongatan 3 A-B, Lund, Sweden, 223 70
Analytics
WallStreet Target Price
254.76 SEKP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ICO
Dividend Analytics ICO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ICO
Stock Valuation ICO
Financials ICO
Results | 2019 | Dynamics |